Peabody, MA -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer, Easy... read more

Privo Technologies, Inc.  attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year... read more

Watch Dr. Goldberg's presentation below regarding localized treatment of cancers in a more safe and effective way and the positive... read more

Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more

Privo Technologies has been awarded ~$2 million in funding from the FDA through its Office of Orphan Product Development (OOPD)... read more

Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment... read more

Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute... read more

Peabody, MA-- Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more

Peabody, MA — Privo Technologies, Inc. (“Privo”, “the Company”), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments announced... read more

BOSTON, Oct. 24, 2018 /PRNewswire/ -- Privo Technologies was granted the green light from the FDA and several hospitals this summer to... read more